obesity

In December 2025, the World Health Organisation (WHO) issued its first guidance on using Glucagon-Like Peptide 1 (GLP 1) therapies for treating obesity 1.  The GLP-1 medications covered include liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Mounjaro / Zepbound in the US). Obesity is a complex chronic disease and a major driver of non-communicable diseases, including… Read more »

Introduction The therapeutic approach to obesity and type 2 diabetes mellitus (T2DM) is evolving in a similar way to how clinicians use antibiotics: targeting several pathways that often produce stronger and more durable effects than acting on a single pathway.   Glucagon-like peptide-1 receptor agonists (GLP-1RAs) laid the foundation, but the complexity of fat mass… Read more »

 On October 14th, 2025, the KHNI hosted an expert scientific webinar; “Adapting Appetites: Scientific and Industry Perspectives on the rise of GLP-1 Medications”.  The expert panel explored the latest science behind Glucagon Like Peptide-1s (GLP-1s), consumer behaviours across regions, the unique nutritional needs of users and what this means for future innovation in food… Read more »

This is a very interesting  article that was first posted in June 2025, and due to its popularity the KHNI would like to draw your attention to this informative read. Over the past decade, the global prevalence of obesity has escalated to alarming levels, prompting significant public health concerns.  In 2022, approximately 1 in 8… Read more »